D. Giri, M. Ittmann (2001)
Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia.The American journal of pathology, 159 1
W. Sande, A. Fahal, H. Verbrugh, A. Belkum (2007)
Polymorphisms in Genes Involved in Innate Immunity Predispose Toward Mycetoma SusceptibilityThe Journal of Immunology, 179
K. Xie (2001)
Interleukin-8 and human cancer biology.Cytokine & growth factor reviews, 12 4
T. Choueiri, S. Vaziri, Erich Jaeger, P. Elson, L. Wood, I. Bhalla, E. Small, V. Weinberg, N. Sein, J. Simko, A. Golshayan, L. Sercia, Ming Zhou, F. Waldman, B. Rini, R. Bukowski, R. Ganapathi (2008)
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.The Journal of urology, 180 3
Daniel Smith, P. Polverini, S. Kunkel, M. Orringer, R. Whyte, M. Burdick, C. Wilke, R. Strieter (1994)
Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinomaThe Journal of Experimental Medicine, 179
IL-8 Contributes to ccRCC Resistance to Sunitinib Cancer Res
M. Sun, G. Lughezzani, P. Perrotte, P. Karakiewicz (2010)
Treatment of metastatic renal cell carcinomaNature Reviews Urology, 7
C. Greenman, P. Stephens, Raffaella Smith, G. Dalgliesh, C. Hunter, G. Bignell, H. Davies, J. Teague, A. Butler, C. Stevens, S. Edkins, S. O’Meara, Imre Vastrik, Esther Schmidt, T. Avis, S. Barthorpe, G. Bhamra, G. Buck, Bhudipa Choudhury, J. Clements, J. Cole, E. Dicks, S. Forbes, K. Gray, Kelly Halliday, R. Harrison, K. Hills, Jonathon Hinton, A. Jenkinson, David Jones, A. Menzies, T. Mironenko, J. Perry, K. Raine, David Richardson, Rebecca Shepherd, Alexandra Small, Calli Tofts, J. Varian, T. Webb, S. West, S. Widaa, A. Yates, Daniel Cahill, David Louis, P. Goldstraw, Andrew Nicholson, F. Brasseur, L. Looijenga, Barbara Weber, Y. Chiew, A. deFazio, Mel Greaves, Anthony Green, P. Campbell, E. Birney, D. Easton, G. Chenevix-Trench, M. Tan, S. Khoo, Bin Teh, S. Yuen, Suet Leung, R. Wooster, P. Futreal, Michael Stratton (2007)
Patterns of somatic mutation in human cancer genomesNature, 446
Kesava Reddy, R. Bukowski (2006)
Phase III Study of Sunitinib Malate (SU11248) Versus Interferon-α as First-Line Treatment in Patients with Metastatic Renal Cell CarcinomaClinical Genitourinary Cancer, 5
R. Motzer, Thomas Hutson, P. Tomczak, M. Michaelson, R. Bukowski, O. Rixe, S. Oudard, S. Négrier, C. Szczylik, Sindy Kim, I. Chen, P. Bycott, C. Baum, R. Figlin (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.The New England journal of medicine, 356 2
G. Bergers, D. Hanahan (2008)
Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 8
A. Koch, P. Polverini, S. Kunkel, L. Harlow, L. DiPietro, V. Elner, S. Elner, R. Strieter (1992)
Interleukin-8 as a macrophage-derived mediator of angiogenesis.Science, 258 5089
(1070)
Cancer Res Cancer Research
O. Casanovas, D. Hicklin, G. Bergers, D. Hanahan (2005)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.Cancer cell, 8 4
Dan Huang, Yan Ding, W. Luo, S. Bender, C. Qian, E. Kort, Zhong-Fa Zhang, K. Vandenbeldt, N. Duesbery, J. Resau, B. Teh (2008)
Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.Cancer research, 68 1
D. Waugh, Catherine Wilson (2008)
The Interleukin-8 Pathway in CancerClinical Cancer Research, 14
L. Ellis, D. Hicklin (2008)
Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted TherapyClinical Cancer Research, 14
(2010)
American Association for Cancer cancerres.aacrjournals.org Downloaded from Published OnlineFirst
Y. Mizukami, Won-Seok Jo, E. Duerr, M. Gala, Jingnan Li, Xiaobo Zhang, M. Zimmer, O. Iliopoulos, L. Zukerberg, Y. Kohgo, M. Lynch, B. Rueda, D. Chung (2005)
Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cellsNature Medicine, 11
Dan Huang, Yan Ding, Yan Li, W. Luo, Zhong-Fa Zhang, J. Snider, K. Vandenbeldt, C. Qian, B. Teh (2010)
Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.Cancer research, 70 3
Premal Patel, Rajendrakumar Chadalavada, R. Chaganti, R. Motzer (2006)
Targeting von Hippel-Lindau Pathway in Renal Cell CarcinomaClinical Cancer Research, 12
Tae-Hee Lee, H. Avraham, Seung-Hoon Lee, S. Avraham (2002)
Vascular Endothelial Growth Factor Modulates Neutrophil Transendothelial Migration via Up-regulation of Interleukin-8 in Human Brain Microvascular Endothelial Cells*The Journal of Biological Chemistry, 277
S. Faivre, G. Demetri, William Sargent, E. Raymond (2007)
Molecular basis for sunitinib efficacy and future clinical developmentNature Reviews Drug Discovery, 6
D. Brat, A. Bellail, Erwin Meir (2005)
The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis.Neuro-oncology, 7 2
R. Kerbel, Joanne Yu, J. Tran, S. Man, A. Viloria‐Petit, G. Klement, B. Coomber, J. Rak (2004)
Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy ApproachesCancer and Metastasis Reviews, 20
J. Ebos, Christina Lee, J. Christensen, A. Mutsaers, R. Kerbel (2007)
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacyProceedings of the National Academy of Sciences, 104
B. Rini, K. Flaherty (2008)
Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.Urologic oncology, 26 5
L. Ellis, D. Hicklin (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activityNature Reviews Cancer, 8
Cancer Research – Unpaywall
Published: Jan 27, 2010
Access the full text.
Sign up today, get DeepDyve free for 14 days.